A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
Public ClinicalTrials.gov record NCT03869684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.
Study identification
- NCT ID
- NCT03869684
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 13 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2019 (Actual)
- Primary completion
- Mar 25, 2020 (Actual)
- Completion
- Apr 24, 2020 (Actual)
- Last update posted
- Apr 20, 2021
2019 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 5
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Senju Investigational Site | Peoria | Arizona | 85381 | — |
| Senju Investigational Site | Phoenix | Arizona | 85053 | — |
| Senju Investigational Site | Pasadena | California | 91107 | — |
| Senju Investigational Site | Redlands | California | 92374 | — |
| Senju Investigational Site | Altamonte Springs | Florida | 32701 | — |
| Senju Investigational Site | Clearwater | Florida | 33761 | — |
| Senju Investigational Site | Melbourne | Florida | 32901 | — |
| Senju Investigational Site | Tallahassee | Florida | 32308 | — |
| Senju Investigational Site | Arlington | Texas | 76012 | — |
| Senju Investigational Site | Houston | Texas | 77030 | — |
| Senju Investigational Site | San Antonio | Texas | 78240 | — |
| Senju Investigational Site | The Woodlands | Texas | 77384 | — |
| Senju Investigational Site | Murray | Utah | 84107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03869684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2021 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03869684 live on ClinicalTrials.gov.